Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
People who have been exposed to both PFAS and PCBs are more likely to be diagnosed with multiple sclerosis (MS). These new ...
By Dennis Thompson HealthDay ReporterWEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic ...
If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...
Paramagnetic rim lesions and other imaging biomarkers that show up on MRI allow patients to be diagnosed and treated much ...
Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...
Heat sensitivity in multiple sclerosis is well known, but doctors say cold weather can also worsen symptoms. From nerve ...
7@four is joined by the team who will be serving the city and surrounding areas: Lead Nurse Practitioner Marion Thomas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback